Without therapy approximately 50% of patients die as a direct result of the disease. Has been shown by recent data to prevent most of the complications and significantly improves survival 2,5,6 MRI of the abdomen shows renal hemosiderosis. Rarely thrombosis of smaller vessels may cause osteonecrosis of the femoral head. Ultrasound, CTA and MRI/MRA may show features of thrombosis of major vessels, particularly in the abdomen. In addition to the anemia from hemolysis, patients suffer from the direct effects of intravascular hemolysis that results in the absorption of nitric oxide, a key molecule in homeostasis, leading to smooth muscle dysfunction and platelet activation, markedly raising the risk of thrombosis 1. These surface proteins usually protect red blood cells and other immune cells from destruction via the complement system, thus a defect in these proteins increases their destruction, leading to the aforementioned clinical presentation 1. Paroxysmal nocturnal hemoglobinuria is caused by a defect in surface proteins of red blood cells, typically due to an acquired mutation in the PIGA gene on the X chromosome in a hematopoietic stem cell 1,7. Median age at diagnosis is in the fourth decade 2. No difference in prevalence between the sexes has been found, M:F = 1:1. Hemoglobinuria is most prominent in the morning after the urine has concentrated overnight during sleep but hemolysis in paroxysmal nocturnal hemoglobinuria is actually a constant process. The study has been published in Clinical Cancer Research.The term comes from a mistaken 19 th century belief that the hemolysis and subsequent hemoglobinuria occurred only intermittently (paroxysmally) and with greater frequency during the night (nocturnal). Additionally, MD Anderson Cancer Center is a large tertiary cancer center, and so trial findings cannot be generalized to community hospitals. The authors acknowledge that their study was limited to trials conducted at a single institution, so the findings are not generalizable. Dearth of patient enrollment prevents the trial from collecting meaningful data that could meet the trial objectives and impact treatment. Lee emphasized the global impact of a failed trial, explaining that the time and resources invested to develop, write, review, and approve a trial and then to open and maintain it, costs money. “Doctors and hospitals need to carefully vet the feasibility of a successful study accrual before opening a trial and be more mindful of investing in the areas of highest potential impact in order to maximize the utilization of available resources,” he added. The authors also found that phase 2-3 and phase 3 trials had a much slower rate of accrual than phase 1 and phase 2 trials.Īccording to Lee, lack of funding might be the primary challenge for patient accrual in national cooperative group trials. Highest odds of slow enrollment were for trials that needed more than 70 days between activation and first enrollment. Time from trial activation to first enrollment (OR = 1.13 per month, P
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |